来凯医药有限公司（来凯医药-B，股票代码：02105）2026年7月13日发布翌日披露报表。公告显示，公司于当日于香港联交所场内回购普通股4万股，占其已发行股本的约0.0089%。回购价格介乎每股港币6.78元至7.45元，累计支付对价约28.26万港元。此次回购股份尚未注销，截至2026年7月13日，公司已发行股份总数为449,331,350股，库藏股为0股。
根据公告，来凯医药-B曾于2026年6月5日通过购回授权，授权可回购总数为44,933,135股。截至目前，在香港联交所及其他证券交易所已累计购回140,000股，占购回授权通过当日公司已发行股份数目的约0.0312%。本次回购后，公司适用的暂止期截至2026年8月12日。公司确认本次股份购回已遵守《香港联合交易所证券上市规则》等相关规定。公告由公司秘书柯晨煜签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.